These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 7754799

  • 1. Effects of 24R,25-dihydroxyvitamin D3 in combination with 1 alpha-hydroxyvitamin D3 in predialysis renal insufficiency: biochemistry and histomorphometry of cancellous bone.
    Birkenhäger-Frenkel DH, Pols HA, Zeelenberg J, Eijgelsheim JJ, Schot R, Nigg AL, Weimar W, Mulder PG, Birkenhäger JC.
    J Bone Miner Res; 1995 Feb; 10(2):197-204. PubMed ID: 7754799
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM, Gordeladze JO, Lyngdal PT, Aarseth HP, Gautvik KM.
    Miner Electrolyte Metab; 1993 Nov; 19(2):78-85. PubMed ID: 8377728
    [Abstract] [Full Text] [Related]

  • 4. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR, Hills E, Norman AW, Bishop JE, Mayer E, Wong SY, Eade Y, Johnson JR, George CR, Collett P.
    Miner Electrolyte Metab; 1985 Nov; 11(6):358-68. PubMed ID: 3877862
    [Abstract] [Full Text] [Related]

  • 5. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
    Mortensen BM, Aarseth HP, Ganss R, Haug E, Gautvik KM, Gordeladze JO.
    Bone; 1993 Nov; 14(2):125-31. PubMed ID: 8334029
    [Abstract] [Full Text] [Related]

  • 6. 24,25-dihydroxyvitamin D3 in combination with 1,25-dihydroxyvitamin D3 ameliorates renal osteodystrophy in rats with chronic renal failure.
    Gal-Moscovici A, Rubinger D, Popovtzer MM.
    Clin Nephrol; 2000 May; 53(5):362-71. PubMed ID: 11305809
    [Abstract] [Full Text] [Related]

  • 7. Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients.
    Popovtzer MM, Levi J, Bar-Khayim Y, Shasha SM, Boner G, Bernheim J, Chaimovitz C, Rubinger D, Gafter U, Gazit D.
    Bone; 1992 May; 13(5):369-77. PubMed ID: 1419378
    [Abstract] [Full Text] [Related]

  • 8. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL, Felsenfeld AJ, Llach F.
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [Abstract] [Full Text] [Related]

  • 9. Effects of 1 alpha-hydroxyvitamin D3 on various stages of predialysis renal bone disease.
    Birkenhäger-Frenkel DH, Pols HA, Zeelenberg J, Eijgelsheim JJ, Kortz RA, Hüpscher EA, van Geelen J, van Berkum FN, Birkenhäger JC.
    Bone Miner; 1989 Jul; 6(3):311-22. PubMed ID: 2758159
    [Abstract] [Full Text] [Related]

  • 10. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
    Djukanović L, Pejanović S, Dragojlović Z, Stosović M.
    Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis.
    Kimura Y, Nakayama M, Kuriyama S, Watanabe S, Kawaguchi Y, Sakai O.
    Clin Nephrol; 1991 Feb; 35(2):72-7. PubMed ID: 2019017
    [Abstract] [Full Text] [Related]

  • 12. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P, Maurouard C, Boudailliez B, Westeel PF, Achard JM, Boitte F, el Esper N, Compagnon M, Maurel G, Bouillon R.
    Nephron; 1992 Feb; 60(2):154-63. PubMed ID: 1552999
    [Abstract] [Full Text] [Related]

  • 13. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.
    Ren Fail; 2005 Feb; 27(2):205-12. PubMed ID: 15807187
    [Abstract] [Full Text] [Related]

  • 14. 24R,25-dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice.
    Ono T, Tanaka H, Yamate T, Nagai Y, Nakamura T, Seino Y.
    Endocrinology; 1996 Jun; 137(6):2633-7. PubMed ID: 8641218
    [Abstract] [Full Text] [Related]

  • 15. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC, Oldham SB, Holick MF, DeLuca HF.
    JAMA; 1975 Oct 06; 234(1):47-52. PubMed ID: 1174223
    [Abstract] [Full Text] [Related]

  • 16. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks.
    Seo EG, Einhorn TA, Norman AW.
    Endocrinology; 1997 Sep 06; 138(9):3864-72. PubMed ID: 9275076
    [Abstract] [Full Text] [Related]

  • 17. [Comparative study of the toxicity of 1 alpha-hydroxyvitamin D3 and 24,25 (RS)-dihydroxyvitamin D3 in rats].
    Khaĭdakov MS, Alekseeva IA, Belakovskiĭ MS, Blazheevich NV, Spirichev VB.
    Farmakol Toksikol; 1985 Sep 06; 48(4):106-9. PubMed ID: 3876239
    [Abstract] [Full Text] [Related]

  • 18. 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.
    Weber K, Goldberg M, Stangassinger M, Erben RG.
    J Bone Miner Res; 2001 Apr 06; 16(4):639-51. PubMed ID: 11315991
    [Abstract] [Full Text] [Related]

  • 19. Hypocalcemic effect of 24R, 25-dihydroxyvitamin D3 in rats.
    Maeda Y, Yamato H, Katoh T, Orimo H.
    In Vivo; 1987 Apr 06; 1(6):347-50. PubMed ID: 2979802
    [Abstract] [Full Text] [Related]

  • 20. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE, Rømer FK, Melsen F, Christensen MS, Hansen HE.
    Clin Nephrol; 1980 Mar 06; 13(3):103-8. PubMed ID: 7379358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.